Literature DB >> 18611060

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Anthe S Zandvliet1, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema.   

Abstract

Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate the selection of dosing schedules, the development of strategies for dose individualization and the application of therapeutic drug monitoring of anticancer agents. This review discusses the role of population pharmacokinetics and pharmacodynamics in clinical oncology to enhance the efficiency of drug development and to support the development of safe and effective dosing regimens for optimal treatment of cancer patients. An overview of published population studies of investigational anticancer agents and established treatment regimens is presented.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18611060     DOI： 10.2165/00003088-200847080-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  281 in total

1.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.

Authors:  Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

2.  Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

3.  Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.

Authors:  H L McLeod; M A Graham; S Aamdal; A Setanoians; Y Groot; B Lund
Journal:  Eur J Cancer       Date:  1996-08       Impact factor: 9.162

4.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

Authors:  W E Evans; M V Relling; J H Rodman; W R Crom; J M Boyett; C H Pui
Journal:  N Engl J Med       Date:  1998-02-19       Impact factor: 91.245

5.  A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

Authors:  Sophie Callies; Dinesh P de Alwis; Adrian Harris; Paul Vasey; Jos H Beijnen; Jan H Schellens; Michael Burgess; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

6.  Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

Authors:  Milly E de Jonge; H J G Desirée van den Bongard; Alwin D R Huitema; Ron A A Mathôt; Hilde Rosing; Paul Baas; Nico van Zandwijk; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

7.  Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.

Authors:  Simon P Joel; Dimitri Papamichael; Fiona Richards; Theresa Davis; Vassili Aslanis; Etienne Chatelut; Kathryn Locke; Maurice L Slevin; Matthew T Seymour
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

8.  Population pharmacokinetics of cisplatin in adult cancer patients.

Authors:  Felix E de Jongh; James M Gallo; Meiyu Shen; Jaap Verweij; Alex Sparreboom
Journal:  Cancer Chemother Pharmacol       Date:  2004-04-30       Impact factor: 3.333

9.  Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.

Authors:  John Carl Panetta; Mark Wilkinson; Ching-Hon Pui; Mary V Relling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

10.  Population pharmacokinetics of carboplatin in children.

Authors:  E Chatelut; A V Boddy; B Peng; H Rubie; M Lavit; A Dezeuze; A D Pearson; H Roché; A Robert; D R Newell; P Canal
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875
View more
  16 in total

Review 1.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

Review 2.  Pharmacokinetic considerations for antibody drug conjugates.

Authors:  Kedan Lin; Jay Tibbitts
Journal:  Pharm Res       Date:  2012-06-28       Impact factor: 4.200

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Authors:  Christophe Meille; Dominique Barbolosi; Joseph Ciccolini; Gilles Freyer; Athanassios Iliadis
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.

Authors:  Huixin Yu; Julie M Janssen; Vincent A de Weger; Bastiaan Nuijen; Rik E Stuurman; Serena Marchetti; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo; Alwin D R Huitema
Journal:  Invest New Drugs       Date:  2020-04-19       Impact factor: 3.850

6.  Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

Authors:  Carmen M Klass; Mi Sun Choe; Selwyn J Hurwitz; Mourad Tighiouart; Xin Zhang; Zhuo Georgia Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-10       Impact factor: 3.147

Review 7.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

8.  Guidelines for clinical evaluation of anti-cancer drugs.

Authors:  Hironobu Minami; Naomi Kiyota; Shiro Kimbara; Yuichi Ando; Tomoya Shimokata; Atsushi Ohtsu; Nozomu Fuse; Yasutoshi Kuboki; Toshio Shimizu; Noboru Yamamoto; Kazuto Nishio; Yutaka Kawakami; Shin-Ichi Nihira; Kazuhiro Sase; Takahiro Nonaka; Hideaki Takahashi; Yukiko Komori; Koshin Kiyohara
Journal:  Cancer Sci       Date:  2021-06-08       Impact factor: 6.716

9.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.

Authors:  R J Keizer; M O Karlsson; A Hooker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-26

10.  Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.

Authors:  Neeltje Steeghs; Ron H J Mathijssen; Judith A M Wessels; Anne-Joy de Graan; Tahar van der Straaten; Mariangela Mariani; Bernard Laffranchi; Silvia Comis; Maja J A de Jonge; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Invest New Drugs       Date:  2010-02-25       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.